Drug intelligence / Profile preview

FLumiY01 + FLumiY02

Development stage: Preclinical
Lead developer: LumiSTAR Biotechnology
Modality: Small Molecules

Overview

FLumiY01 + FLumiY02 is a small molecule drug discovery program being developed by LumiSTAR Biotechnology. The program is currently in the discovery phase and is targeting inflammatory diseases and fibrosis. LumiSTAR Biotechnology utilizes its proprietary induced pluripotent stem cell (iPSC) platform to identify and develop these small molecule candidates through phenotypic screening. Specific molecular targets and mechanisms of action for these assets have not been publicly disclosed by the company as of early 2024.

Beyond the preview

Go deeper on FLumiY01 + FLumiY02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FLumiY01 + FLumiY02.

Explore the full profile